This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-HLA-A2.1 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the HLA-A2.1 as well as the biological activity of IL2. In vitro analysis revealed that the IL2-FuP supported mainly proliferation and lymphokine-activated killer cell activity. IL2 fused immunocytokine significantly accumulated in the tumor, which led to retardation of tumor growth. This immunocytokine was designed for treating tumor.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.